Pharmacological Management of Delirium

Cognitive Impairment Clinical Trial

— PMD  

Official title:

Pharmacological Management of Delirium

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00842608
• Other study ID #: IA0145
• Secondary ID: R01AG034205
• Status: Completed
• Phase: N/A
• Start date: February 2009
• Est. completion date: July 2015

Study information

• Verified date: August 2018
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to develop and test the feasibility of using a specific pharmacological protocol to reduce delirium burden among older adults in the Intensive Care Unit (ICU). The study will test the efficacy of a pharmacological intervention in reducing delirium severity and duration as well as length of stay and mortality compared to usual care.

Description:

In 2005, approximately 2.7 million Americans aged 65 and older spent at least one day in the intensive care unit (ICU), costing Medicare an estimated $27.5 billion. It is estimated that while hospitalized, up to 80% of these older ICU patients had delirium, an acute brain failure that is an independent predictor of morbidity and mortality which often goes unrecognized. Older adults with delirium are more prone to falls, injuries, pressure ulcers and restraints, complications which may also contribute to prolonged ICU and hospital length of stay, higher mortality rates, poorer functional status, limited rehabilitation, increased institutionalization, and higher health care costs. The literature supports treatment with a combination of a reduction in the use of benzodiazepines and anticholinergics and the use of low-dose neuroleptics such as haloperidol. However, there have been no randomized controlled trials evaluating the efficacy of this approach on reducing delirium severity, duration, and complications.

Building upon the e-CHAMP study, ("Enhancing Care for Hospitalized Older Adults With Memory Problems;" see NCT00182832), a recently completed quality improvement project tested the effectiveness of cognitive screening coupled with computerized decision support in reducing delirium and other hospital-related complications among 424 older adults hospitalized on the medical wards, which found that many of the older adults entering the study had already experienced delirium in the ICU prior to their transfer to the wards. This study will test a pharmacologic intervention that allows a more targeted approach to the care of older adults with delirium while still recognizing the clinicians' role in controlling symptoms and providing intensive care.

The hypothesis is that patients in the intervention arm as compared to usual care will have:

• reduced delirium severity, as measured by the Delirium Rating Scale (DRS-R-98), at one week following randomization or hospital discharge

• fewer hospital days with delirium or coma as determined by the Confusion Assessment Method in the ICU (CAM-ICU)

• shorter hospital lengths of stay

• lower ICU, hospital, and 30-day mortality

Recruitment information / eligibility

• Status: Completed
• Enrollment: 551
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older

• Hospitalized on an ICU ward

• Delirium based on the RASS and the CAM-ICU assessments at any day during ICU stay

• English speaking

Exclusion Criteria:

• Admitted directly to a regular non-ICU ward

• Previously enrolled in the study

• Not eligible for delirium assessment as determined by RASS scores

• Prior history of severe mental illness

• Alcohol-related delirium

• Pregnant or nursing

• Have had an aphasic stroke

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Cognitive Impairment
• Delirium

Intervention

Behavioral:
• Reduced exposure to anticholinergics
Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug. Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can & cannot receive Haldol

Procedure:
• Reduced exposure to benzodiazepines
Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation

Drug:
• Haloperidol
0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital

Procedure:
• Usual care
May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium

Locations

Country	Name	City	State
United States	Eskenazi Hospital	Indianapolis	Indiana
United States	Methodist Hospital	Indianapolis	Indiana
United States	University Hospital	Indianapolis	Indiana

Sponsors (2)

Lead Sponsor	Collaborator
Indiana University	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Days Free of Delirium and Coma		Admission through day 8 of stay
Secondary	Hospital Length of Stay Post Randomization		Participants were followed for the duration of hospital stay, an average of 11 days
Secondary	Mortality		ICU, in-hospital, 30-days post hospitalization